Veracyte (VCYT) Liabilities and Shareholders Equity (2016 - 2025)
Historic Liabilities and Shareholders Equity for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $1.4 billion.
- Veracyte's Liabilities and Shareholders Equity rose 727.56% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 billion, marking a year-over-year increase of 1042.65%. This contributed to the annual value of $1.3 billion for FY2024, which is 1660.49% up from last year.
- As of Q3 2025, Veracyte's Liabilities and Shareholders Equity stood at $1.4 billion, which was up 727.56% from $1.3 billion recorded in Q2 2025.
- Veracyte's 5-year Liabilities and Shareholders Equity high stood at $1.4 billion for Q3 2025, and its period low was $1.0 billion during Q1 2021.
- Over the past 5 years, Veracyte's median Liabilities and Shareholders Equity value was $1.2 billion (recorded in 2022), while the average stood at $1.2 billion.
- Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 30018.97% in 2021, then crashed by 509.11% in 2022.
- Quarter analysis of 5 years shows Veracyte's Liabilities and Shareholders Equity stood at $1.2 billion in 2021, then dropped by 2.64% to $1.2 billion in 2022, then fell by 3.59% to $1.1 billion in 2023, then rose by 16.6% to $1.3 billion in 2024, then grew by 5.21% to $1.4 billion in 2025.
- Its Liabilities and Shareholders Equity stands at $1.4 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.